CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Glatiramer acetate

Last Updated: April 29, 2009
Result type: Reports
Project Number: SR0164-000
Product Line: Reimbursement Review

Generic Name: Glatiramer acetate

Brand Name: Copaxone

Manufacturer: Teva Pharmaceutical Industries Ltd.

Therapeutic Area: Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis

Indications: Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: November 25, 2009

Recommendation Type: Do not list